ZOLEDRONIC ACID FRESENIUS KABI 4 MG/5 ML CONC. FOR SOLUTION FOR INFUSION

Zoledronic Acid Fresenius Kabi is a vital medication designed to address serious bone-related conditions. This concentrate for solution for infusion contains Zoledronic Acid, a potent bisphosphonate that effectively inhibits bone resorption. It is primarily used in patients with advanced malignancies involving bone to prevent skeletal-related events and to treat hypercalcemia of malignancy.

This medication is administered intravenously under strict medical supervision, ensuring its targeted action and efficacy. Its specific formulation delivers 4 mg of Zoledronic Acid in a 5 ml vial, providing a concentration of 0.8 mg/ml.

Benefits of Use

• Significantly reduces the incidence of skeletal-related events such as pathological fractures, spinal cord compression, and the need for radiation or surgery to bone in patients with advanced cancer affecting the bones.
• Highly effective in managing and treating hypercalcemia of malignancy, a severe complication of cancer characterized by abnormally high calcium levels in the blood.
• Offers a prolonged duration of action, which can contribute to a more manageable treatment regimen for patients.
• Ensures complete bioavailability of the active ingredient through intravenous administration, allowing for precise dosing and rapid onset of action.

How to Use

1. Zoledronic Acid Fresenius Kabi must be prepared and administered by a qualified healthcare professional.
2. It is given as a single intravenous infusion.
3. The infusion should be administered slowly over a period of at least 15 minutes.
4. Patients are typically advised to be adequately hydrated before receiving the infusion, particularly those with hypercalcemia.
5. The specific dosage and frequency of administration will be determined by your doctor based on your medical condition, kidney function, and other individual factors.
6. Regular monitoring of renal function, serum calcium, phosphate, and magnesium levels is essential during treatment.

Caution & Warnings

• This medication is for intravenous use only and must be administered by a healthcare professional. Do not attempt self-administration.
• Not recommended for use in pregnant or breastfeeding women due to potential risks to the fetus or infant.
• Exercise caution in patients with pre-existing kidney impairment; dosage adjustments may be necessary, and renal function should be closely monitored.
• There is a risk of osteonecrosis of the jaw (ONJ), particularly in cancer patients. Maintain excellent oral hygiene and report any oral symptoms to your doctor.
• Close monitoring for hypocalcemia (low blood calcium) is required. Calcium and Vitamin D supplementation may be prescribed to prevent this.
• Patients may experience flu-like symptoms, fever, or bone, joint, and muscle pain. Consult your doctor if these symptoms become severe.
• Ensure adequate hydration before and during the infusion to minimize the risk of renal complications.
• Inform your doctor about all medications you are currently taking, including over-the-counter drugs and herbal supplements.

Ingredients

Active Ingredient: Zoledronic Acid 4 mg (equivalent to 4.264 mg Zoledronic Acid monohydrate)

Other Excipients: Mannitol, Sodium citrate, Water for injections

Product Details

• Dosage Form: Concentrate for solution for infusion
• Route of Administration: Intravenous
• Vial Size: 5 ml
• Strength: 4 mg Zoledronic Acid per 5 ml vial (0.8 mg/ml)
• Manufacturer: Fresenius Kabi
• Therapeutic Class: Bisphosphonate